Finance

Lists
Why is ZTS up 2,37%?
Dive Deeper
ZTS:NYSE
Zoetis Inc
74,81 $
+2,37%
(+1,73) 1D
74,81 $
0,00% (0,00)
After hours
Closed: 9 қаз., 16:03:16 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
73,04 $
High
74,85 $
Low
73,00 $
Mkt. cap
30,91 млрд
Avg. vol.
4,59 млн
Volume
2,91 млн
Dividend
2,83%
Quarterly dividend
0,53 $
Ex-dividend date
2026 ж. 20 шіл.
P/E ratio
12,31
52-wk high
148,30 $
52-wk low
68,77 $
EPS
6,08 $
Beta
0,74
Shares outstanding
413,22 млн
No. of employees
14 мың
Open
73,04 $
High
74,85 $
Low
73,00 $
Mkt. cap
30,91 млрд
Avg. vol.
4,59 млн
Volume
2,91 млн
Dividend
2,83%
Quarterly dividend
0,53 $
Ex-dividend date
2026 ж. 20 шіл.
P/E ratio
12,31
52-wk high
148,30 $
52-wk low
68,77 $
EPS
6,08 $
Beta
0,74
Shares outstanding
413,22 млн
No. of employees
14 мың
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14,5 мың
Founded1952
HeadquartersParsippany-Troy Hills, Нью-Джерси, Америка Құрама Штаттары
SectorPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 11 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
4
Hold
7
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current 74,81 $
115,00 $ (+53,72%)
Average
90,71 $ (+21,25%)
Lowest
80,00 $ (+6,94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Jonathan Block
Stifel Nicolaus
Hold
Reiterated
-
-
09/18/2026
Steve Scala
TD Cowen
Buy
Reiterated
94,00 $
+25,7%
08/25/2026
Glen Santangelo
Barclays
Hold
Reiterated
85,00 $
+13,6%
08/17/2026
Chris Schott
J.P. Morgan
Buy
Maintained
115,00 $
+53,7%
08/10/2026
Daniel Grosslight
Citi
Buy
Maintained
96,00 $
+28,3%
08/11/2026
David Westenberg
Piper Sandler
Hold
Maintained
80,00 $
+6,9%
08/10/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
85,00 $
+13,6%
08/10/2026
Andrea Alfonso
UBS
Hold
Reiterated
80,00 $
+6,9%
08/07/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
95,00 $
+27%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
05/08/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
131,00 $
+75,1%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
160,00 $
+113,9%
02/26/2026
Last report
2026 ж. 06 там.
Fiscal period
Q2 2026
1,87 $ / 1,85 $
+0,95%beat
Revenue / Est. (USD)
2,47 млрд / 2,51 млрд
-1,75%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
2,40 млрд
2,39 млрд
2,26 млрд
2,47 млрд
Cost of goods sold
682,00 млн
711,00 млн
640,00 млн
670,00 млн
Cost of revenue
682,00 млн
711,00 млн
640,00 млн
670,00 млн
Research and development expenses
170,00 млн
199,00 млн
180,00 млн
173,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
572,00 млн
618,00 млн
584,00 млн
589,00 млн
Operating expense
774,00 млн
848,00 млн
795,00 млн
793,00 млн
Total operating expenses
1,46 млрд
1,56 млрд
1,44 млрд
1,46 млрд
Operating income
944,00 млн
828,00 млн
827,00 млн
1,00 млрд
Other non operating income
-
-6,00 млн
-1,00 млн
-2,00 млн
EBT including unusual items
887,00 млн
761,00 млн
758,00 млн
866,00 млн
EBT excluding unusual items
899,00 млн
780,00 млн
779,00 млн
948,00 млн
Income tax expense
166,00 млн
158,00 млн
157,00 млн
175,00 млн
Effective tax rate
18,71%
20,76%
20,71%
20,21%
Other operating expenses
-
-
-
-
Net income
721,00 млн
603,00 млн
601,00 млн
691,00 млн
Net profit margin
30,04%
25,26%
26,57%
28,00%
Earnings per share
1,70
1,48
1,53
1,87
Interest and investment income
26,00 млн
25,00 млн
21,00 млн
16,00 млн
Interest expense
-58,00 млн
-57,00 млн
-62,00 млн
-61,00 млн
Net interest expenses
-32,00 млн
-32,00 млн
-41,00 млн
-45,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,07 млрд
903,00 млн
946,00 млн
1,12 млрд
Gain or loss from assets sale
-
-
-6,00 млн
-1,00 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары